

# GAVI Vaccine Investment Strategy Project

## *Vaccine Portfolio Analysis*



Applied Strategies  
400 S. El Camino Real, Suite 375  
San Mateo, CA 94402  
[www.appliedstrategies.com](http://www.appliedstrategies.com)

**October 29, 2008**

A banner image showing a landscape with a green field, a blue sky, and a single acacia tree on the right. Two diagonal lines, possibly representing a road or a structure, cross the scene from the top corners towards the center.

# Vaccine Portfolio Analysis

## CONTENTS

- *Vaccine Options*
- Portfolio Option 'A'
- Portfolio Option 'B'
- Portfolio Option 'C'
- Portfolio Option Summary
- Appendix
  - Metric Summary by Strategy
  - Portfolio Analysis without India
  - Portfolio Analysis with Conservative Adoption Forecast

# Vaccine Options

## POTENTIAL PORTFOLIO COMPONENTS

Disease (# of countries)*	Strategy
Cholera (31)	<ul style="list-style-type: none"> <li>• 1-15yo Campaign Every 3 Years</li> <li>• 1-49yo Campaign Every 3 Years</li> </ul>
HPV (60)	<ul style="list-style-type: none"> <li>• Routine 10yo Female Vaccination</li> </ul>
JE (13)	<ul style="list-style-type: none"> <li>• Routine Infant Vaccination with boost after 12 mos + 1-15yo Catch-up Campaign</li> </ul>
Rabies (49)	<ul style="list-style-type: none"> <li>• Post-Exposure Prophylaxis</li> </ul>
Rubella (46)	<ul style="list-style-type: none"> <li>• Rapid Impact               <ul style="list-style-type: none"> <li>– Routine 1yo Vaccination with boost at 4yo +</li> <li>– 2-19yo Campaign +</li> <li>– 20-29yo WBCA Campaign</li> </ul> </li> <li>• Delayed Impact               <ul style="list-style-type: none"> <li>– Routine 1yo Vaccination with boost at 4yo +</li> <li>– 15-39yo WBCA Campaign</li> </ul> </li> </ul>
Typhoid (24)	<ul style="list-style-type: none"> <li>• Routine Infant Vaccination with boost after 12mos</li> <li>• Routine Infant Vaccination with boost after 12mos + 1-15yo Catch-up</li> <li>• 2-15yo Campaign Every 3 Years</li> <li>• 5-15yo Campaign Every 3 years</li> </ul>

\* Countries expected to adopt in 2009-2020 time period, excluding countries that have already adopted



# Vaccine Options

## CHOLERA

- Currently licensed vaccine products are not ideal for implementation in GAVI countries (potential need to revaccinate large cohorts every three years with a 2 dose regimen due to a limited duration of protection)
- Their value, including effectiveness, has varied depending on age cohort and country setting studied
- There is currently no expert consensus on endemicity and optimal vaccination strategy
- Compared to other investment options, cholera has a relatively low return on investment in terms of cost per death averted

### **GAVI Working Group recommendation:**

- Cholera should remain a priority for the GAVI Alliance, but not be included in current portfolio options
- The Board should consider alternative investments in operational research (\$6M indicative envelope proposed) to generate further knowledge regarding the most appropriate strategies for cholera vaccination strategy
- Industry should be encouraged to continue investment in cholera vaccine products that are appropriate for use the developing world

A banner image showing a landscape with a green field, a blue sky, and a single acacia tree on the right. Two diagonal lines, possibly representing a road or a bridge, cross the scene from the bottom corners towards the center.

# Vaccine Portfolio Analysis

## CONTENTS

- Vaccine Options
- ***Portfolio Option 'A'***
- Portfolio Option 'B'
- Portfolio Option 'C'
- Portfolio Option Summary
- Appendix
  - Metric Summary by Strategy
  - Portfolio Analysis without India
  - Portfolio Analysis with Conservative Adoption Forecast

# Portfolio Option 'A'


## PORTFOLIO DEFINITION

Disease (# of countries)*	Vaccination Strategy	Rationale
HPV (60)	Routine 10yo Female Vaccination	<ul style="list-style-type: none"> <li>• Supports maximize disease burden impact portfolio strategy theme</li> <li>• All diseases result in severe long-term sequelae</li> <li>• Proven safe and efficacious vaccines</li> <li>• SAGE recommendation current or pending</li> <li>• Consensus on vaccination strategy</li> <li>• All vaccines applicable to consensus vaccination strategy</li> </ul>
JE (13)	Routine Infant Vaccination with boost after 12 mos + 1-15yo Catch-up Campaign	
Rubella (46) <i>Delayed Impact</i>	Routine 1yo Vaccination with boost at 4yo + 15-39yo WBCA Campaign	

\* Countries expected to adopt in 2009-2020 time period, excluding countries that have already adopted

# Portfolio Option 'A'


## VACCINE AVAILABILITY



# Portfolio Option 'A'

## ADOPTION FORECAST

*Integrated Adoption Forecast  
2009-2020*




	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HPV	0	3	1	2	3	4	9	15	9	14	0	0
JE	0	0	4	4	1	2	1	1	0	0	0	0
Rubella	0	10	4	1	6	2	4	6	7	2	1	3

# Portfolio Option 'A'

## DEMAND FORECAST

*Integrated Adoption Forecast  
2009-2020*



	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HPV Routine	0	0	1	1	3	4	6	17	26	37	46	52
JE Routine	0	0	2	7	11	15	17	20	22	23	24	24
JE 1-15 yo Catch-up	0	0	58	33	54	2	11	17	0	0	0	0
Rubella Routine	0	32	33	32	64	70	75	87	93	98	102	107
Rubella 15-39yo WCBA	0	175	40	1	31	3	14	13	14	4	0	3

# Portfolio Option 'A'

## GAVI VACCINE COST FORECAST

*Integrated Adoption Forecast  
2009-2020*

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	3	7	11	25	35	59	125	184	250	263	300	<b>1,261</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	290	175	208	42	58	63	33	35	35	35	<b>974</b>
Rubella <i>Delayed Impact Version</i>	0	74	25	11	33	24	30	33	36	34	34	36	<b>370</b>
<b>Portfolio A Total</b>	<b>0</b>	<b>77</b>	<b>322</b>	<b>197</b>	<b>266</b>	<b>102</b>	<b>146</b>	<b>221</b>	<b>252</b>	<b>318</b>	<b>332</b>	<b>372</b>	<b>2,606</b>
<b>Portfolio A Cumulative</b>	<b>0</b>	<b>77</b>	<b>399</b>	<b>596</b>	<b>862</b>	<b>964</b>	<b>1,110</b>	<b>1,331</b>	<b>1,583</b>	<b>1,901</b>	<b>2,233</b>	<b>2,606</b>	



# Portfolio Option 'A'

## IMPLEMENTATION COST FORECAST

*Integrated Adoption Forecast  
2009-2020*

Disease	Country Implementation Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV Routine	0	4	7	11	20	26	39	90	136	191	238	272	<b>1,033</b>
JE Routine + Catch-up	0	0	30	29	40	39	52	67	60	64	67	67	<b>516</b>
<i>Routine + boost</i>	0	0	6	18	29	39	46	54	60	60	67	67	452
<i>1-15yo Catch-up</i>	0	0	24	11	11	1	6	12	0	0	0	0	64
Rubella Delayed	0	66	30	16	42	36	44	50	57	55	56	59	<b>511</b>
<i>Routine + boost</i>	0	14	16	16	32	35	38	45	49	53	56	58	413
<i>15-39yo WCBA</i>	0	51	13	0	10	1	5	4	8	2	0	1	97
<b>Total Country Costs</b>	<b>\$0</b>	<b>\$69</b>	<b>\$67</b>	<b>\$57</b>	<b>\$102</b>	<b>\$102</b>	<b>\$135</b>	<b>\$206</b>	<b>\$253</b>	<b>\$311</b>	<b>\$360</b>	<b>\$398</b>	<b>\$2,060</b>

Global Partner Implementation Costs (\$M)	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total (\$M)
		\$19	\$48	\$50	\$49	\$47	\$44	\$47	\$51	\$46	\$46	\$37	\$20

# Portfolio Option 'A'

## METRIC SUMMARY

*Integrated Adoption Forecast  
2009-2020*

Strategy	Total Vaccine Cost (\$M)	GAVI Vaccine Cost (\$M)	Country Vaccine Cost (\$M)	Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/Death Averted	GAVI Cost (\$)/Case Averted	Long-Term Sequelae	Country Imp Costs (\$M)
<b>HPV</b> Routine 10yo Female Vaccination	\$1,293	\$1,261	\$31	707	n/a	870	\$1,784	\$1,449	Severe	\$1,033
<b>JE</b> Routine Infant Vaccination with boost after 12 mos + 1-15yo Catch-up Campaign	\$1,034	\$974	\$60	140	93	765	\$6,967	\$1,274	Severe	\$516
<b>Rubella (delayed impact)</b> Routine 1yo Vaccination with boost at 4yo + 15-39yo WBCA Campaign	\$540	\$370	\$170	22*	13*	110*	\$16,742*	\$3,363*	Severe	\$511
<b>Portfolio 'A' Total</b>	<b>\$2,867</b>	<b>\$2,606</b>	<b>\$261</b>	<b>869</b>	<b>106</b>	<b>1,745</b>	<b>\$2,998</b>	<b>\$1,493</b>	<b>n/a</b>	<b>\$2,060</b>

*\* Includes CRS deaths and cases only*

# Portfolio Option 'A'

## TOTAL PORTFOLIO COST

*Integrated Adoption Forecast  
2009-2020*

Cost Component	Cost
GAVI Vaccine Cost (\$M)	2,606
Country Vaccine Co-Pay Cost (\$M)	261
<b>Total Vaccine Cost (\$M)</b>	<b>\$2,867</b>
Country Implementation Cost (\$M)	2,060
Partner Associated Cost (\$M)	503
<b>TOTAL COST (\$M)</b>	<b>\$5,430</b>

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted
869	106	1,745	\$2,998	\$1,493

A banner image showing a landscape with a green field, a blue sky, and a single acacia tree on the right. Two diagonal lines, possibly representing a road or a structure, cross the scene from the bottom corners towards the top.

# Vaccine Portfolio Analysis

## CONTENTS

- Vaccine Options
- Portfolio Option 'A'
- ***Portfolio Option 'B'***
- Portfolio Option 'C'
- Portfolio Option Summary
- Appendix
  - Metric Summary by Strategy
  - Portfolio Analysis without India
  - Portfolio Analysis with Conservative Adoption Forecast

# Portfolio Option 'B'

## PORTFOLIO DEFINITION

*Integrated Adoption Forecast  
2009-2020*


Strategy	Total Vaccine Cost (\$M)	GAVI Vaccine Cost (\$M)	Country Vaccine Cost (\$M)	Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/Death Averted	GAVI Cost (\$)/Case Averted	Long-Term Sequelae	Country Imp Costs (\$M)
HPV Routine	\$1,293	\$1,261	\$31	707	n/a	870	\$1,784	\$1,449	Severe	\$1,033
JE Routine + Catch-Up	\$1,034	\$974	\$60	140	93	765	\$6,967	\$1,274	Severe	\$516
Rubella (delayed impact)	\$540	\$370	\$170	22*	13*	110*	\$16,742*	\$3,363*	Severe	\$511
<b>PORTFOLIO 'A' TOTAL</b>	<b>\$2,867</b>	<b>\$2,606</b>	<b>\$261</b>	<b>869</b>	<b>106</b>	<b>1,745</b>	<b>\$2,998</b>	<b>\$1,493</b>	<b>n/a</b>	<b>\$2,060</b>
Rabies PEP	\$2,945	\$2,882	\$63	483	24	n/a	\$5,970	n/a	Mild-None	\$90
Rubella Rapid (incremental cost)	\$344	\$238	\$106	52*	18*	307*	\$4,577*	\$775*	Severe (CRS)	\$327
Typhoid Routine	\$211	\$182	\$29	154	154	15,485	\$1,182	\$12	Mild-None	\$643
<b>Typhoid Routine + Catch-up</b>	<b>\$529</b>	<b>\$459</b>	<b>\$70</b>	<b>178</b>	<b>160</b>	<b>18,093</b>	<b>\$2,579</b>	<b>\$25</b>	<b>Mild-None</b>	<b>\$763</b>
Typhoid 2-15yo Campaign	\$443	\$364	\$79	39	8	4,248	\$9,259	\$86	Mild-None	\$218
Typhoid 5-15yo Campaign	\$510	\$432	\$78	36	n/a	3,855	\$11,905	\$112	Mild-None	\$197

*Deemed next best investment given health impact and return on GAVI investment*

*\* Includes CRS deaths and cases only*

# Portfolio Option 'B'


## VACCINE AVAILABILITY



# Portfolio Option 'B'

## ADOPTION FORECAST

*Integrated Adoption Forecast  
2009-2020*




	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HPV	0	3	1	2	3	4	9	15	9	14	0	0
JE	0	0	4	4	1	2	1	1	0	0	0	0
Rubella	0	10	4	1	6	2	4	6	7	2	1	3
Typhoid	0	0	3	2	1	6	2	2	2	4	1	1

# Portfolio Option 'B'

## DEMAND FORECAST

*Integrated Adoption Forecast  
2009-2020*



	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HPV Routine	0	0	1	1	3	4	6	17	26	37	46	52
JE Routine	0	0	2	7	11	15	17	20	22	23	24	24
JE 1-15yo Catch-up	0	0	58	33	54	2	11	17	0	0	0	0
Rubella Routine	0	32	33	32	64	70	75	87	93	98	102	107
Rubella 15-39yo WCBA	0	175	40	1	31	3	14	13	14	4	0	3
Typhoid Routine	0	0	1	3	5	9	14	20	25	30	34	38
Typhoid 1-15yo Catch-up	0	0	4	13	16	33	50	32	33	51	29	6

# Portfolio Option 'B'

## GAVI VACCINE COST FORECAST

*Integrated Adoption Forecast  
2009-2020*

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	3	7	11	25	35	59	125	184	250	263	300	<b>1,261</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	290	175	208	42	58	63	33	35	35	35	<b>974</b>
Rubella <i>Delayed Impact Version</i>	0	74	25	11	33	24	30	33	36	34	34	36	<b>370</b>
Typhoid <i>Routine + 1-15yo Catch-up</i>	0	0	9	20	21	59	66	38	77	82	45	42	<b>459</b>
<b>Portfolio B Total</b>	<b>0</b>	<b>77</b>	<b>331</b>	<b>217</b>	<b>287</b>	<b>161</b>	<b>213</b>	<b>259</b>	<b>328</b>	<b>401</b>	<b>377</b>	<b>414</b>	<b>3,065</b>
<b>Portfolio B Cumulative</b>	<b>0</b>	<b>77</b>	<b>408</b>	<b>625</b>	<b>912</b>	<b>1,073</b>	<b>1,286</b>	<b>1,545</b>	<b>1,873</b>	<b>2,274</b>	<b>2,651</b>	<b>3,065</b>	

# Portfolio Option 'B'

## IMPLEMENTATION COST FORECAST

*Integrated Adoption Forecast  
2009-2020*

Disease	Country Implementation Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV Routine	0	4	7	11	20	26	39	90	136	191	238	272	<b>1,033</b>
JE Routine + Catch-up	0	0	30	29	40	39	52	67	60	64	67	67	<b>516</b>
<i>Routine + boost</i>	0	0	6	18	29	39	46	54	60	60	67	67	452
<i>1-15yo Catch-up</i>	0	0	24	11	11	1	6	12	0	0	0	0	64
Rubella Delayed	0	66	30	16	42	36	44	50	57	55	56	59	<b>510</b>
<i>Routine + boost</i>	0	14	16	16	32	35	38	45	49	53	56	58	413
<i>15-39yo WCBA</i>	0	51	13	0	10	1	5	4	8	2	0	1	97
Typhoid Routine + Catch-up	0	0	8	19	26	52	68	78	111	132	129	139	<b>762</b>
<i>Routine = boost</i>	0	0	3	10	19	34	51	71	90	108	122	135	642
<i>1-15yo Catch-up</i>	0	0	5	9	7	18	18	7	21	24	7	4	120
<b>Total Country Costs</b>	<b>\$0</b>	<b>\$69</b>	<b>\$75</b>	<b>\$76</b>	<b>\$128</b>	<b>\$153</b>	<b>\$203</b>	<b>\$284</b>	<b>\$364</b>	<b>\$442</b>	<b>\$490</b>	<b>\$538</b>	<b>\$2,823</b>

Global Partner Implementation Costs (\$M)	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total (\$M)
		\$19	\$48	\$55	\$54	\$51	\$49	\$50	\$54	\$49	\$50	\$39	\$21

# Portfolio Option 'B'

## METRIC SUMMARY

*Integrated Adoption Forecast  
2009-2020*

Strategy	Total Vaccine Cost (\$M)	GAVI Vaccine Cost (\$M)	Country Vaccine Cost (\$M)	Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted	Long-Term Sequelae	Country Imp Costs (\$M)
HPV Routine	\$1,293	\$1,261	\$31	707	n/a	870	\$1,784	\$1,449	Severe	\$1,033
JE Routine + Catch-Up	\$1,034	\$974	\$60	140	93	765	\$6,967	\$1,274	Severe	\$516
Rubella (delayed impact)	\$540	\$370	\$170	22	13	110*	\$16,742	\$3,363	Severe	\$511
Typhoid Routine + Catch-up	\$529	\$459	\$70	178	160	18,093	\$2,579	\$25	Mild-None	\$763
<b>PORTFOLIO 'B' TOTAL</b>	<b>\$3,396</b>	<b>\$3,065</b>	<b>\$331</b>	<b>1,046</b>	<b>266</b>	<b>19,838</b>	<b>\$2,929</b>	<b>\$155</b>	<b>n/a</b>	<b>\$2,823</b>

*\* Includes CRS deaths and cases only*

# Portfolio Option 'B'

## TOTAL PORTFOLIO COST

*Integrated Adoption Forecast  
2009-2020*

Cost Component	Cost
GAVI Vaccine Cost (\$M)	3,065
Country Co-Pay Cost (\$M)	331
<b>Total Vaccine Cost (\$M)</b>	<b>\$3,396</b>
Country Implementation Cost (\$M)	2,823
Partner Cost (\$M)	537
<b>TOTAL COST (\$M)</b>	<b>\$6,756</b>

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted
1,046	266	19,838	\$2,929	\$155

A banner image showing a landscape with a green field, a blue sky, and a single tree on the horizon. The image is framed by a blue border with diagonal lines.

# Vaccine Portfolio Analysis

## CONTENTS

- Vaccine Options
- Portfolio Option 'A'
- Portfolio Option 'B'
- ***Portfolio Option 'C'***
- Portfolio Option Summary
- Appendix
  - Metric Summary by Strategy
  - Portfolio Analysis without India
  - Portfolio Analysis with Conservative Adoption Forecast

# Portfolio Option 'C'

## PORTFOLIO DEFINITION

*Integrated Adoption Forecast  
2009-2020*


Strategy	Total Vaccine Cost (\$M)	GAVI Vaccine Cost (\$M)	Country Vaccine Cost (\$M)	Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted	Long-Term Sequelae	Country Imp Costs (\$M)
HPV Routine	\$1,293	\$1,261	\$31	707	n/a	870	\$1,784	\$1,449	Severe	\$1,033
JE Routine + Catch-Up	\$1,034	\$974	\$60	140	93	765	\$6,967	\$1,274	Severe	\$516
Rubella (delayed impact)	\$540	\$370	\$170	22	13	110*	\$16,742	\$3,363	Severe	\$511
Typhoid Routine + Catch-up	\$529	\$459	\$70	178	160	18,093	\$2,579	\$25	Mild-None	\$763
<b>PORTFOLIO 'B' TOTAL</b>	<b>\$3,396</b>	<b>\$3,065</b>	<b>\$331</b>	<b>1,046</b>	<b>266</b>	<b>19,838</b>	<b>\$2,929</b>	<b>\$155</b>	<b>n/a</b>	<b>\$2,823</b>
Rabies PEP	\$2,945	\$2,882	\$63	483	24	n/a	\$5,970	n/a	Mild-None	\$90
Rubella Rapid (incremental)	\$344	\$238	\$106	52*	18*	307*	\$4,577*	\$775*	Severe (CRS)	\$327

*Deemed worthwhile investment  
if GAVI funds available*

*\* Includes CRS deaths and cases only*

# Portfolio Option 'C'

## VACCINE AVAILABILITY



# Portfolio Option 'C'

## ADOPTION FORECAST


*Integrated Adoption Forecast  
2009-2020*

	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HPV	0	3	1	2	3	4	9	15	9	14	0	0
JE	0	0	4	4	1	2	1	1	0	0	0	0
Rubella	0	10	4	1	6	2	4	6	7	2	1	3
Typhoid	0	0	3	2	1	6	2	2	2	4	1	1
Rabies	0	9	10	3	9	9	4	2	1	2	0	0

# Portfolio Option 'C'

## DEMAND FORECAST

*Integrated Adoption Forecast  
2009-2020*



	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HPV Routine	0	0	1	1	3	4	6	17	26	37	46	52
JE Routine	0	0	2	7	11	15	17	20	22	23	24	24
JE 1-15yo Catch-up	0	0	58	33	54	2	11	17	0	0	0	0
Rubella Routine	0	32	33	32	64	70	75	87	93	98	102	107
Rubella 1-19yo Catch-up	0	406	88	4	106	14	50	53	53	15	0	9
Rubella 20-29yo WCBA	0	119	26	1	22	2	10	9	10	3	0	2
Typhoid Routine	0	0	1	3	5	9	14	20	25	30	34	38
Typhoid 1-15yo Catch-up	0	0	4	13	16	33	50	32	33	51	29	6
Rabies PEP	0	24	26	27	31	34	39	41	42	44	45	45

# Portfolio Option 'C'

## GAVI VACCINE COST FORECAST

*Integrated Adoption Forecast  
2009-2020*

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	3	7	11	25	35	59	125	184	250	263	300	<b>1,261</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	290	175	208	42	58	63	33	35	35	35	<b>974</b>
Typhoid <i>Routine + 1-15yo Catch-up</i>	0	0	9	20	21	59	66	38	77	82	45	42	<b>459</b>
Rabies PEP	0	223	244	244	250	270	276	281	277	278	268	272	<b>2,882</b>
Rubella <i>Rapid Impact Version</i>	0	191	51	12	66	29	45	50	52	39	34	39	<b>608</b>
<b>Portfolio C Total</b>	<b>0</b>	<b>417</b>	<b>599</b>	<b>463</b>	<b>570</b>	<b>436</b>	<b>504</b>	<b>556</b>	<b>622</b>	<b>683</b>	<b>646</b>	<b>689</b>	<b>6,185</b>
<b>Portfolio C Cumulative</b>	<b>0</b>	<b>417</b>	<b>1,017</b>	<b>1,480</b>	<b>2,050</b>	<b>2,485</b>	<b>2,989</b>	<b>3,545</b>	<b>4,167</b>	<b>4,850</b>	<b>5,496</b>	<b>6,185</b>	

# Portfolio Option 'C'

## IMPLEMENTATION COST FORECAST

*Integrated Adoption Forecast  
2009-2020*

Disease	Country Implementation Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV Routine	0	4	7	11	20	26	39	90	136	191	238	272	<b>1,033</b>
JE Routine + Catch-up	0	0	30	29	40	39	52	67	60	64	67	67	<b>516</b>
<i>Routine + boost</i>	0	0	6	18	29	39	46	54	60	60	67	67	452
<i>1-15yo Catch-up</i>	0	0	24	11	11	1	6	12	0	0	0	0	64
Typhoid Routine + Catch-up	0	0	8	19	26	52	68	78	111	132	129	139	<b>762</b>
<i>Routine + boost</i>	0	0	3	10	19	34	51	71	90	108	122	135	642
<i>1-15yo Catch-up</i>	0	0	5	9	7	18	18	7	21	24	7	4	120
Rabies PEP	0	5	6	6	7	8	9	10	10	10	10	10	90
Rubella Rapid	0	200	60	17	110	42	65	71	90	62	57	64	<b>838</b>
<i>Routine + boost</i>	0	14	16	16	32	35	38	45	49	53	56	39	414
<i>2-19yo Catch-up</i>	0	151	35	1	71	6	23	23	35	8	0	4	357
<i>20-29yo WCBA</i>	0	35	9	0	7	1	4	3	6	1	1	1	67
<b>Total Country Costs</b>	<b>\$0</b>	<b>\$209</b>	<b>\$111</b>	<b>\$83</b>	<b>\$203</b>	<b>\$166</b>	<b>\$233</b>	<b>\$315</b>	<b>\$406</b>	<b>\$460</b>	<b>\$501</b>	<b>\$553</b>	<b>\$3,241</b>

Global Partner Implementation Costs (\$M)	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total (\$M)
		\$20	\$56	\$64	\$59	\$57	\$55	\$53	\$56	\$51	\$53	\$39	\$21

# Portfolio Option 'C'

## METRIC SUMMARY

*Integrated Adoption Forecast  
2009-2020*

Strategy	Total Vaccine Cost (\$M)	GAVI Vaccine Cost (\$M)	Country Vaccine Cost (\$M)	Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/Death Averted	GAVI Cost (\$)/Case Averted	Long-Term Sequelae	Country Imp Costs (\$M)
HPV Routine	\$1,293	\$1,261	\$31	707	n/a	870	\$1,784	\$1,449	Severe	\$1,033
JE Routine + Catch-Up	\$1,034	\$974	\$60	140	93	765	\$6,967	\$1,274	Severe	\$516
Typhoid Routine + Catch-up	\$529	\$459	\$70	178	160	18,093	\$2,579	\$25	Mild-None	\$763
Rabies PEP	\$2,945	\$2,882	\$63	483	24	0	\$5,970	n/a	Mild-None	\$90
Rubella Rapid	\$884	\$608	\$276	74*	31*	417*	\$8,222*	\$1,459*	Severe	\$838
<b>PORTFOLIO 'C' TOTAL</b>	<b>\$6,684</b>	<b>\$6,185</b>	<b>\$499</b>	<b>1,582</b>	<b>308</b>	<b>20,145</b>	<b>\$3,910</b>	<b>\$307</b>	<b>n/a</b>	<b>\$3,240</b>

*\* Includes CRS deaths and cases only*

# Portfolio Option 'C'

## TOTAL PORTFOLIO COST

*Integrated Adoption Forecast  
2009-2020*

Cost Component	Cost
GAVI Vaccine Cost (\$M)	6,185
Country Co-Pay Cost (\$M)	499
<b>Total Vaccine Cost (\$M)</b>	<b>\$6,684</b>
Country Implementation Cost (\$M)	3,241
Partner Cost (\$M)	584
<b>TOTAL COST (\$M)</b>	<b>\$10,509</b>

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted
1,582	308	20,145	\$3,910	\$307

A banner image showing a landscape with a green field, a blue sky, and a single acacia tree on the right. Two diagonal lines, possibly representing a bridge or a path, cross the scene from the top corners towards the center.

# Vaccine Portfolio Analysis

## CONTENTS

- Vaccine Options
- Portfolio Option 'A'
- Portfolio Option 'B'
- Portfolio Option 'C'
- ***Portfolio Option Summary***
- Appendix
  - Metric Summary by Strategy
  - Portfolio Analysis without India
  - Portfolio Analysis with Conservative Adoption Forecast

# Portfolio Option Summary

## COST SUMMARY

*Integrated Adoption Forecast  
2009-2020*

Cost Component	Portfolio Option 'A'	Portfolio Option 'B'	Portfolio Option 'C'
GAVI Vaccine Cost (\$M)	2,606	3,065	6,185
Country Co-Pay Cost (\$M)	261	331	499
<b>Total Vaccine Cost (\$M)</b>	<b>\$2,867</b>	<b>\$3,396</b>	<b>\$6,684</b>
Country Implementation Cost (\$M)	2,060	2,823	3,241
Partner Cost (\$M)	503	537	584
<b>TOTAL COST (\$M)</b>	<b>\$5,430</b>	<b>\$6,756</b>	<b>\$10,509</b>

# Portfolio Option Summary

## METRIC SUMMARY

*Integrated Adoption Forecast  
2009-2020*

Metric	Portfolio Option 'A'	Portfolio Option 'B'	Portfolio Option 'C'
Total Projected Deaths Averted (x1000)	869	1,046	1,582
Total Projected Deaths Averted <5yo (x1000)	106	266	308
Total Cases Averted (x1000)	1,745	19,838	20,145
GAVI Cost per Death Averted (\$)	\$2,998	\$2,929	\$3,910
GAVI Cost per Case Averted (\$)	\$1,493	\$155	\$307

# Portfolio Option Summary

## PORTFOLIO SUMMARY

*Integrated Adoption Forecast  
2009-2020*

Metric	Portfolio Option 'A'	Portfolio Option 'B'	Portfolio Option 'C'
GAVI Vaccine Cost (\$M)	2,606	3,065	6,185
Country Vaccine Co-Pay Cost (\$M)	261	331	499
Total Vaccine Cost (\$M)	\$2,867	\$3,396	\$6,684
Total Projected Deaths Averted (x1000)	869	1,046	1,582
Total Projected Deaths Averted <5yo (x1000)	106	266	308
Total Cases Averted (x1000)	1,745	19,838	20,145
GAVI Cost per Death Averted (\$)	\$2,998	\$2,929	\$3,910
GAVI Cost per Case Averted (\$)	\$1,493	\$155	\$307

A banner image showing a landscape with a green field, a blue sky, and a single acacia tree on the right. Two diagonal lines, possibly representing a road or a structure, cross the scene from the bottom corners towards the center.

# Vaccine Portfolio Analysis

## CONTENTS

- Vaccine Options
- Portfolio Option 'A'
- Portfolio Option 'B'
- Portfolio Option 'C'
- Portfolio Option Summary
- ***Appendix***
  - ***Metric Summary by Strategy***
  - Portfolio Analysis without India
  - Portfolio Analysis with Conservative Adoption Forecast

# Metric Summary by Strategy

Strategy	Total Vaccine Cost (\$M)	GAVI Vaccine Cost (\$M)	Country Vaccine Cost (\$M)	Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted	Country Imp Costs (\$M)
<b>Cholera</b> 1-15yo Campaign Every 3 Years	\$1,480	\$1,227	253	130	33	6,654	\$9,462	\$184	\$425
<b>Cholera</b> 1-49yo Campaign Every 3 Years	\$3,198	\$2,659	\$538	132	10	6,046	\$20,075	\$440	\$888
<b>HPV</b> Routine 10yo Female Vaccination	\$1,293	\$1,261	\$31	707	n/a	870	\$1,784	\$1,449	\$1,033
<b>JE</b> Routine Infant Vaccination with boost after 12 mos + 1-15yo Catch-up Campaign	\$1,034	\$974	\$60	140	93	765	\$6,967	\$1,274	\$516
<b>Rabies</b> Post-Exposure Prophylaxis	\$2,945	\$2,882	\$63	483	24	n/a	\$5,970	n/a	\$90
<b>Rubella (rapid impact)</b> Routine 1yo Vaccination with boost at 4yo + 2-19yo Campaign + 20-29yo WBCA Campaign	\$884	\$608	\$276	74*	31*	417*	\$8,222*	\$1,459*	\$838
<b>Rubella (delayed impact)</b> Routine 1yo Vaccination with boost at 4yo + 15-39yo WBCA Campaign	\$540	\$370	\$170	22*	13*	110*	\$16,742*	\$3,363*	\$511
<b>Rubella Incremental</b> From Delayed to Rapid	\$344	\$238	\$106	52*	18*	307*	\$4,577*	\$775*	\$327
<b>Typhoid</b> Routine Infant Vaccination with boost after 12mos	\$211	\$182	\$29	154	154	15,485	\$1,182	\$12	\$643
<b>Typhoid</b> Routine Infant Vaccination with boost after 12mos + 1-15yo Catch-up	\$529	\$459	\$70	178	160	18,093	\$2,579	\$25	\$763
<b>Typhoid</b> 2-15yo Campaign Every 3 Years	\$443	\$364	\$79	39	8	4,248	\$9,259	\$86	\$218
<b>Typhoid</b> 5-15yo Campaign Every 3 Years	\$510	\$432	\$78	36	n/a	3,855	\$11,985	\$112	\$197

A banner image showing a landscape with a single acacia tree on a green plain under a blue sky, framed by a dark blue border with white diagonal lines.

# Vaccine Portfolio Analysis

## CONTENTS

- Vaccine Options
- Portfolio Option 'A'
- Portfolio Option 'B'
- Portfolio Option 'C'
- Portfolio Option Summary
- ***Appendix***
  - Metric Summary by Strategy
  - ***Portfolio Analysis without India***
  - Portfolio Analysis with Conservative Adoption Forecast

# Portfolio Option 'A'

## GAVI VACCINE COST FORECAST Without India

*Integrated Adoption Forecast  
2009-2020*

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	3	7	11	25	35	59	95	132	178	183	201	<b>929</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	290	175	208	42	58	63	33	35	35	35	<b>974</b>
Rubella <i>Delayed Impact Version</i>	0	17	19	5	21	12	17	21	23	21	21	23	<b>198</b>
<b>Portfolio A Total</b>	<b>0</b>	<b>20</b>	<b>316</b>	<b>191</b>	<b>254</b>	<b>89</b>	<b>134</b>	<b>179</b>	<b>188</b>	<b>233</b>	<b>239</b>	<b>259</b>	<b>2,100</b>
<b>Portfolio A Cumulative</b>	<b>0</b>	<b>20</b>	<b>336</b>	<b>526</b>	<b>780</b>	<b>869</b>	<b>1,003</b>	<b>1,182</b>	<b>1,369</b>	<b>1,602</b>	<b>1,841</b>	<b>2,100</b>	

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted
667	100	1,460	\$3,149	\$1,439

# Portfolio Option 'B'

## GAVI VACCINE COST FORECAST *Without India*

*Integrated Adoption Forecast  
2009-2020*

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	3	7	11	25	35	59	95	132	178	183	201	<b>929</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	290	175	208	42	58	63	33	35	35	35	<b>974</b>
Rubella <i>Delayed Impact Version</i>	0	17	19	5	21	12	17	21	23	21	21	23	<b>198</b>
Typhoid <i>Routine + 1-15yo Catch-up</i>	0	0	9	20	21	59	66	38	37	38	36	33	<b>356</b>
<b>Portfolio B Total</b>	<b>0</b>	<b>20</b>	<b>324</b>	<b>211</b>	<b>275</b>	<b>149</b>	<b>200</b>	<b>216</b>	<b>225</b>	<b>271</b>	<b>275</b>	<b>292</b>	<b>2,456</b>
<b>Portfolio B Cumulative</b>	<b>0</b>	<b>20</b>	<b>344</b>	<b>555</b>	<b>830</b>	<b>978</b>	<b>1,178</b>	<b>1,394</b>	<b>1,619</b>	<b>1,890</b>	<b>2,165</b>	<b>2,456</b>	

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/Death Averted	GAVI Cost (\$)/Case Averted
818	238	16,725	\$3,005	\$147

# Portfolio Option 'C'

## GAVI VACCINE COST FORECAST Without India

*Integrated Adoption Forecast  
2009-2020*

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	3	7	11	25	35	59	95	132	178	183	201	<b>929</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	290	175	208	42	58	63	33	35	35	35	<b>974</b>
Typhoid <i>Routine + 1-15yo Catch-up</i>	0	0	9	20	21	59	66	38	37	38	36	33	<b>356</b>
Rabies PEP	0	37	56	58	83	105	129	141	140	145	140	142	<b>1,176</b>
Rubella <i>Rapid Impact Version</i>	0	49	44	6	54	16	33	37	39	25	21	26	<b>350</b>
<b>Portfolio C Total</b>	<b>0</b>	<b>90</b>	<b>405</b>	<b>270</b>	<b>391</b>	<b>258</b>	<b>344</b>	<b>374</b>	<b>381</b>	<b>420</b>	<b>415</b>	<b>437</b>	<b>3,785</b>
<b>Portfolio C Cumulative</b>	<b>0</b>	<b>90</b>	<b>495</b>	<b>765</b>	<b>1,156</b>	<b>1,414</b>	<b>1,758</b>	<b>2,132</b>	<b>2,513</b>	<b>2,933</b>	<b>3,348</b>	<b>3,785</b>	

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/Death Averted	GAVI Cost (\$)/Case Averted
1,058	259	16,911	3,578	224

# Portfolio Option Summary

## PORTFOLIO SUMMARY *Without India*

## *Integrated Adoption Forecast 2009-2020*

Cost	Portfolio Option 'A'	Portfolio Option 'B'	Portfolio Option 'C'
GAVI Vaccine Cost (\$M)	2,100	2,456	3,785
Country Vaccine Co-Pay Cost (\$M)	179	234	329
Total Vaccine Cost (\$M)	\$2,279	\$2,690	\$4,114
Total Projected Deaths Averted (x1000)	667	818	1,058
Total Projected Deaths Averted <5yo (x1000)	100	238	259
Total Cases Averted (x1000)	1,460	16,725	16,911
GAVI Cost per Death Averted (\$)	\$3,149	\$3,005	\$3,578
GAVI Cost per Case Averted (\$)	\$1,439	\$147	\$224

A banner image showing a landscape with a green field, a blue sky, and a single acacia tree on the right. Two diagonal lines, possibly representing a bridge or a structure, cross the sky from the top corners towards the center.

# Vaccine Portfolio Analysis






## CONTENTS

- Vaccine Options
- Portfolio Option 'A'
- Portfolio Option 'B'
- Portfolio Option 'C'
- Portfolio Option Summary
- ***Appendix***
  - Metric Summary by Strategy
  - Portfolio Analysis without India
  - ***Portfolio Analysis with Conservative Adoption Forecast***

# Portfolio Analysis

## COUNTRY ADOPTION FORECAST

### *Integrated vs. Conservative Forecast 2009-2020*



# Portfolio Option 'A'

## GAVI VACCINE COST FORECAST

## Conservative Adoption Forecast 2009-2020

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	0	0	2	4	8	12	15	21	31	47	67	<b>208</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	4	32	57	7	62	9	37	13	81	19	<b>320</b>
Rubella <i>Delayed Impact Version</i>	0	10	74	10	22	17	22	32	31	31	31	33	<b>314</b>
<b>Portfolio A Total</b>	0	10	78	45	82	33	96	57	89	75	160	118	<b>842</b>
<b>Portfolio A Cumulative</b>	0	10	88	133	215	248	344	400	489	564	724	842	

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted
200	46	572	\$4,207	\$1,471

# Portfolio Option 'B'

## GAVI VACCINE COST FORECAST

## Conservative Adoption Forecast 2009-2020

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	0	0	2	4	8	12	15	21	31	47	67	<b>208</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	4	32	57	7	62	9	37	13	81	19	<b>320</b>
Rubella <i>Delayed Impact Version</i>	0	10	74	10	22	17	22	32	31	31	31	33	<b>314</b>
Typhoid <i>Routine + 1-15yo Catch-up</i>	0	0	0	9	11	5	7	6	7	19	29	31	<b>123</b>
<b>Portfolio B Total</b>	0	10	78	54	93	38	102	62	96	93	189	149	<b>965</b>
<b>Portfolio B Cumulative</b>	0	10	88	142	235	273	375	438	534	627	816	965	

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/ Death Averted	GAVI Cost (\$)/ Case Averted
240	80	4,617	\$4,023	\$209

# Portfolio Option 'C'

## GAVI VACCINE COST FORECAST

## Conservative Adoption Forecast 2009-2020

Disease	GAVI Vaccine Procurement Costs (\$M)												Total (\$M)
	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
HPV <i>Routine Immunization</i>	0	0	0	2	4	8	12	15	21	31	47	67	<b>208</b>
JE <i>Routine + 1-15yo Catch-up</i>	0	0	4	32	57	7	62	9	37	13	81	19	<b>320</b>
Typhoid <i>Routine + 1-15yo Catch-up</i>	0	0	0	9	11	5	7	6	7	19	29	31	<b>123</b>
Rabies PEP	0	73	155	236	229	245	244	256	269	267	261	266	<b>2,499</b>
Rubella <i>Rapid Impact Version</i>	0	32	198	15	46	22	27	58	47	36	33	34	<b>546</b>
<b>Portfolio C Total</b>	0	105	357	294	346	287	352	343	380	365	451	417	<b>3,695</b>
<b>Portfolio C Cumulative</b>	0	105	461	755	1,102	1,388	1,740	2,083	2,463	2,828	3,279	3,695	

Deaths Averted (x1000)	<5 Deaths Averted (x1000)	Cases Averted (x1000)	GAVI Cost (\$)/Death Averted	GAVI Cost (\$)/Case Averted
718	117	4,906	5,149	753

# Portfolio Option Summary

## PORTFOLIO SUMMARY

## *Conservative Adoption Forecast 2009-2020*

Metric	Portfolio Option 'A'	Portfolio Option 'B'	Portfolio Option 'C'
GAVI Vaccine Cost (\$M)	842	965	3,695
Country Vaccine Co-Pay Cost (\$M)	175	193	351
Total Vaccine Cost (\$M)	1,017	1,158	4,047
Total Projected Deaths Averted (x1000)	200	240	718
Total Projected Deaths Averted <5yo (x1000)	46	80	117
Total Cases Averted (x1000)	572	4,617	4,906
GAVI Cost per Death Averted (\$)	\$4,207	\$4,023	\$5,149
GAVI Cost per Case Averted (\$)	\$1,471	\$209	\$753